Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma?
Victorian Infectious Diseases Reference Laboratories, North Melbourne, Victoria, Australia.
Nadia
N
Warner
Stephen
S
Locarnini
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives; D000998:Antiviral Agents / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000209:etiology* / Q000473:pathology; D018450:Disease Progression; D024882:Drug Resistance, Viral / Q000187:drug effects; D006515:Hepatitis B virus / Q000187:drug effects; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects; D008113:Liver Neoplasms / Q000209:etiology* / Q000473:pathology; D063065:Organophosphonates / Q000009:adverse effects
D000998:Antiviral Agents; D063065:Organophosphonates; D019259:Lamivudine; C053001:adefovir; D000225:Adenine